About FDA

NCTR Research Highlights

Red envelope icon for GovdeliveryGet e-mail updates when this information changes.


Current Highlight from May 13, 2016

Role of Drug Metabolism in Amiodarone-Induced Liver Injury

NCTR scientists have shown that metabolism of amiodarone (an anti-arrhythmic drug) by cytochrome P450 (CYP) isoforms 3A4 and 1A1 is linked to its observed hepatotoxicity. A panel of HepG2-derived cell lines that stably express 14 individual human CYPs were treated with clinically relevant concentrations of amiodarone and assayed for cell viability. Increased toxicity and higher levels of the hepatotoxic metabolite desethylamiodarone were observed in the cell lines overexpressing CYP3A4 and CYP1A1. Amiodarone is a commonly used anti-arrhythmic drug that is often associated with numerous adverse effects, including liver injury; however, the mechanisms of this toxicity are not well understood. These results, together with the well-known inter-individual variation in CYP3A4 expression levels, could affect the clinical use of amiodarone. A manuscript reporting the study is available online at Toxicology Lettersdisclaimer icon.
 

For additional information, please contact Matthew Bryant, Lei Guo, Division of Biochemical Toxicology, FDA/NCTR.

 

 

Contact FDA

870-543-7000
National Center for Toxicological Research

Food and Drug Administration

3900 NCTR Road

Jefferson, AR 72079

Page Last Updated: 05/16/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.